Heads up, money-watchers: Insmed just got the green light from the FDA for Brinsupri, the first-ever daily pill for a tough lung disease called NCFB. The stock popped to a 25-year high, and retail traders are buzzing. Why? This drug finally gives half a million Americans a new option, and with minimal side effects, it could be a game-changer. If you’re into biotech or just like a good underdog story, keep an eye on this one—it could be the next big thing in your portfolio. #Business #Market #stocks